U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Vaccines, Blood & Biologics
  3. Guidance, Compliance & Regulatory Information (Biologics)
  4. Biologics Guidances
  5. General Biologics Guidances
  6. Withdrawn - Submitting Type V Drug Master Files to the Center for Biologics Evaluation and Research; Draft Guidance for Industry
  1. General Biologics Guidances

Withdrawn - Submitting Type V Drug Master Files to the Center for Biologics Evaluation and Research; Draft Guidance for Industry

The guidance document entitled "Draft Guidance for Industry - Submitting Type V Drug Master Files to the Center for Biologics Evaluation and Research" was withdrawn on August 9, 2010. Additional information is available on CBER's web site (https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/new-drug-application-nda-and-abbreviated-new-drug-application-anda-cber-regulated-products).

If you have any questions about submitting drug master files to the Center for Biologics Evaluation and Research, please contact the Office of Communication, Outreach and Development toll-free at 1-800-835-4709 (toll 301-827-1800) or by email at matt@fda.hhs.gov.

 

Back to Top